BeStock  
Stocks › Biotechnology › MNPR

Monopar Therapeutics MNPR

US equityMarket cap rank #3617Biotechnology
$69.00 −$1.29 (-1.84%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $67.35 -2.40%
Open$68.50
Prev close$70.29
Day range$67.36 – $69.86
Volume132.6K
Market cap$467.60M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership112.8%+3.47 pts vs. prior quarter
Institutions holding126+12 vs. prior quarter
Insider trades (recent)28 buys / 22 sellsNet buying
Short interest16.44% of floatDays to cover 8.8 · as of 30 Oct 2026
Short-sale volume share17.8%5-day average of daily volume

Short-sale volume as % of daily volume

7%13%18%24%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$298.8K (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

+$604.9KSuper−$306.1KBig−$608.8KMid+$223.9KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 50.8% of shares outstanding.

Largest holders

  • Janus Henderson Group plc19.55%
  • RA Capital Management, L.P.9.94%
  • Tactic Pharma LLC8.46%
  • AstraZeneca PLC7.79%
  • BlackRock5.04%
  • Deerfield Management Company, L.P.4.82%
  • Saturn V Capital Management LP4.65%
  • Artal Group S.A.4.02%

By investor type

  • Mutual Fund49.74%
  • Hedge Fund24.13%
  • VC/PE Fund20.69%
  • Private Company9.22%
  • Public Company8.78%
  • Individual/Insider7.25%
  • Government Pension Fund0.13%
  • Insurance Company0.09%

Reported short interest has risen from 13.22% to 16.44% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
State Street Global Advisors Mutual Fund 2026/Q3 +137,220 3.4%
UBS Asset Management Mutual Fund 2026/Q3 +58,012 1.3%
Jane Street Group, LLC Private Company 2026/Q3 +43,683 0.6%
Morgan Stanley Public Company 2026/Q3 +20,118 0.6%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +20,118 0.6%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +8,247 3.2%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +7,738 0.1%
Rafferty Asset Management, LLC Mutual Fund 2026/Q3 +5,959 0.1%
Chandler Robinson Individual/Insider 2026/Q3 +5,457 2.5%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +5,980 0.1%
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +157,423 2.3%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +143,339 2.1%
TCG Crossover Management, LLC VC/PE Fund 2026/Q3 +71,224 3.0%
Longaeva Partners L.P. Mutual Fund 2026/Q3 +55,834 0.8%
Driehaus Capital Management LLC Mutual Fund 2026/Q3 +50,884 1.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
3 Nov 2026 Kim Tsuchimoto Director Derivative Exercise and Sale -4,090 $72.21 11,486
1 Nov 2026 Raymond Anderson Independent Director Derivative Exercise and Sale -3,142 $70.04 5,373
19 Oct 2026 Chandler Robinson Chief Executive Officer Sale to Issuer -597 $92.59 166,942
30 Sep 2026 Christopher Starr Co-Founder & Independent Executive Chairman of the Board Derivative Exercise and Sale -8,400 $79.67 15,053
29 Sep 2026 Andrew Cittadine Chief Operating Officer Derivative Exercise and Sale -1,944 $79.67 58,054
29 Sep 2026 Andrew Cittadine Chief Operating Officer Derivative Exercise and Retained +2,440 – 58,054
29 Sep 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Sale -4,344 $79.67 167,539
29 Sep 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Retained +5,457 – 167,539
29 Sep 2026 Quan Vu CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer Derivative Exercise and Sale -180 $79.67 2,655
29 Sep 2026 Quan Vu CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer Derivative Exercise and Retained +434 – 2,655
23 Sep 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Sale -29,056 $89.79 162,082
25 Aug 2026 Patrice Rioux Acting Chief Medical Officer Derivative Exercise and Sale -1 $111.26 5,065
25 Aug 2026 Patrice Rioux Acting Chief Medical Officer Other Derivative Acquisition +1,380 $0.01 –
25 Aug 2026 Patrice Rioux Acting Chief Medical Officer Derivative Exercise and Retained +1,379 $0.01 5,065
25 Aug 2026 Kim Tsuchimoto Director Automatic Disposition -4,090 $113.84 11,486
25 Aug 2026 Kim Tsuchimoto Director Derivative Exercise and Sale -4,090 $113.84 11,486
25 Aug 2026 Kim Tsuchimoto Director Other Derivative Acquisition +4,090 $30.00 8,140
24 Aug 2026 Raymond Anderson Independent Director Derivative Exercise and Sale -3,142 $113.05 5,373
24 Aug 2026 Raymond Anderson Independent Director Other Derivative Acquisition +3,142 $30.00 3,480
7 Jul 2026 Arthur Klausner Former Independent Director Intent to Sell (Form 144) -5,000 – –

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 1,103,516 16.4% 8.8
15 Oct 2026 1,128,617 16.8% 7.1
30 Sep 2026 1,086,279 16.2% 6.0
15 Sep 2026 844,226 12.6% 7.2
31 Aug 2026 852,425 12.7% 4.5
14 Aug 2026 887,188 13.2% 3.5

Discussion

No comments yet — be the first to weigh in on MNPR.

Sign in to join the discussion.

Scroll to Top